The short version of IGF-1 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-22. Anything still debated is marked as such rather than presented as settled.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
(Some contemporary authors question even this single exception, preferring to consistently follow the valence configurations and place helium over beryllium.) There are eight columns in this periodic table fragment, corresponding to at most eight outer-shell electrons. A period begins when a new shell starts filling. Finally, the colouring illustrates the blocks: the elements in the s-block (coloured red) are filling s orbitals, while those in the p-block (coloured yellow) are filling p orbitals.
=== Inflammation === Neuroinflammation is considered a contributing mechanism in Parkinson's disease. Research has shown lasting activation of the brain's immune cells, microglia, in regions affected by the disease, suggesting that inflammation may play a role in the gradual loss of dopamine-producing neurons. While immune responses can be protective in the short term, chronic inflammation may damage neurons over time. Dopaminergic neurons appear to be particularly vulnerable under inflammatory conditions. The normal production and breakdown of dopamine already place these cells under higher stress than other neurons. When inflammation is present, this may increase the neurons' susceptibility to damage and speed up degeneration. Changes in dopamine signaling may then influence immune activity in the brain, creating a feedback loop to further worsen neuronal loss.
While the recreational use of (and consequently the distribution of) cannabis is illegal in majority of countries, recreational distribution is legal in some countries, such as Canada, and medical distribution is permitted in some places, such as 38 of the 50 US states (although importation and distribution is still federally prohibited). Beginning in 2014, Uruguay became the first country to legalize cultivation, sale, and consumption of cannabis for recreational use for adult residents. In 2018, Canada became the second country to legalize use, sale and cultivation of cannabis. The first few weeks were met with extremely high demand, most shops being out of stock after operating for only four days. Cannabis use is tolerated in some areas, most notably the Netherlands, which has legalized the possession and licensed sale (but not cultivation) of the drug. Many nations have decriminalized the possession of small amounts of marijuana. Due to the hardy nature of the cannabis plant, marijuana is grown all across the world; today, it is the world's most popular illegal drug with the highest level of availability. Cannabis is grown legally in many countries for industrial, non-drug use (known as hemp) as well. Cannabis-hemp may also be planted for other non-drug domestic purposes, such as seasoning that occurs in Aceh. The demand for cannabis around the world, coupled with the drug's relative ease of cultivation, makes the illicit cannabis trade one of the primary ways in which organized criminal groups finance many of their activities.
Sources: en.wikipedia.org
The vagina is the birth canal for the delivery of a baby. When labor nears, several signs may occur, including vaginal discharge and the rupture of membranes (water breaking). The latter results in a gush or small stream of amniotic fluid from the vagina. Water breaking most commonly happens at the beginning of labor. It happens before labor if there is a premature rupture of membranes, which occurs in 10% of cases. Among women giving birth for the first time, Braxton Hicks contractions are mistaken for actual contractions, but they are instead a way for the body to prepare for true labor. They do not signal the beginning of labor, but they are usually very strong in the days leading up to labor. As the body prepares for childbirth, the cervix softens, thins, moves forward to face the front, and begins to open. This allows the fetus to settle into the pelvis, a process known as lightening. As the fetus settles into the pelvis, pain from the sciatic nerves, increased vaginal discharge, and increased urinary frequency can occur. While lightening is likelier to happen after labor has begun for women who have given birth before, it may happen ten to fourteen days before labor in women experiencing labor for the first time. The fetus begins to lose the support of the cervix when contractions begin. With cervical dilation reaching 10 cm to accommodate the head of the fetus, the head moves from the uterus to the vagina. The elasticity of the vagina allows it to stretch to many times its normal diameter in order to deliver the child.
== Staining Mechanism == Van Gieson’s stain is an acidic dye mixture. It utilizes the different affinities of its two components for tissue proteins. Acid fuchsin is a large poly-ionic dye (a sulfonated triphenylmethane) that strongly binds to collagen fibers in a strongly acidic solution, while picric acid (a small trinitrophenol molecule) penetrates and binds more to cytoplasmic proteins and muscle. Additionally, Picric acid provides the acidic pH necessary for the stain mechanism. Van Gieson stain essentially differentiates cytoplasm and muscle from collagen. Mechanistic studies suggest that acid fuchsin molecules bind to collagen mainly via hydrogen bonds, collagen’s triple-helix stays relatively open during and after dye-binding. Meanwhile, picric acid binds more via hydrophobic and ionic interactions in dense cytoplasmic protein networks. In practice, tissue sections are often first stained with an iron hematoxylin for nuclei, then with Van Gieson solution.
== Career == Baldwin began acting professionally as a teenager, landing the role of Ricky Linderman in the Chicago-set film My Bodyguard (1980). That same year he appeared in Robert Redford's Academy Award-winning drama Ordinary People as Kevin Stillman. In the early 1980s he continued with supporting roles in films including D.C. Cab (1983) and Reckless (1984). By the late 1980s he had moved into higher-profile studio productions, including Stanley Kubrick's Vietnam War film Full Metal Jacket (1987), in which he played the Marine nicknamed "Animal Mother," and the crime thriller Next of Kin (1989). In the 1990s he appeared in a run of mainstream features including Predator 2 (1990), the western biopic Wyatt Earp (1994) portraying Tom McLaury, and the science-fiction blockbuster Independence Day (1996). He later played Captain Wilkins in Roland Emmerich's Revolutionary War film The Patriot (2000). On television, Baldwin became a regular cast member of Joss Whedon's science-fiction series Firefly (2002–2003) as the mercenary Jayne Cobb, and reprised the role in the continuation film Serenity (2005). From 2007 to 2012 he played the National Security Agency agent John Casey on NBC's action-comedy series Chuck. His other television work includes a regular role on ABC's Day Break (2006–2007) and a lead role on the 1996–1997 drama series The Cape as Col. Jack Riles. He made a brief on-screen return to the schoolyard premise of My Bodyguard with a cameo in the comedy Drillbit Taylor (2008), noted as an explicit nod to his earlier film.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.